|
|
Prepublished online as a Blood First Edition Paper on October 24, 2002; DOI 10.1182/blood-2002-07-2341.
 Previous Article | Table of Contents | Next Article 
Blood, 1 March 2003, Vol. 101, No. 5, pp. 1981-1983
NEOPLASIA
Brief report
Both B and T lymphocytes may be clonally involved in
myelofibrosis with myeloid metaplasia
Terra L. Reeder,
Richard J. Bailey,
Gordon W. Dewald, and
Ayalew Tefferi
From the Mayo Clinic, Rochester, MN.
A combination of magnetic cell sorting (MACS) and fluorescent in
situ hybridization (FISH) techniques was used to detect clonal cytogenetic markers in different myeloid and lymphoid cell types of the
peripheral blood from 4 patients with myelofibrosis with myeloid
metaplasia (MMM) that was associated with either a 13q or a 20q
karyotypic abnormality. Interphase cytogenetics studies demonstrated
abnormal clonal FISH signal patterns in neutrophil, myeloid, erythroid,
megakaryocyte, and B- and T-cell preparations in 3 of the 4 patients.
In one patient, FISH results were within normal limits in T cells and
slightly abnormal in B cells. In general, the percentage of abnormal
nuclei was variable in both lymphocyte populations but always higher in
B lymphocytes compared with T lymphocytes. The current study provides
direct evidence for the clonal involvement of both B and T lymphocytes
in MMM. A larger study is needed to clarify the relevance of the
observed interpatient heterogeneity in clonal constitution.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Vener, N. S. Fracchiolla, U. Gianelli, R. Calori, F. Radaelli, A. Iurlo, S. Caberlon, G. Gerli, L. Boiocchi, and G. L. Deliliers
Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis
Blood,
February 15, 2008;
111(4):
1862 - 1865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Wagner-Ballon, D. F. Pisani, T. Gastinne, M. Tulliez, R. Chaligne, C. Lacout, F. Aurade, J.-L. Villeval, P. Gonin, W. Vainchenker, et al.
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice
Blood,
July 1, 2007;
110(1):
345 - 353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Primary myelofibrosis and its paraneoplastic stromal effects
Haematologica,
May 1, 2007;
92(5):
577 - 579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and R. E. Richard
Myeloproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
172 - 227.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ishii, E. Bruno, R. Hoffman, and M. Xu
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
Blood,
November 1, 2006;
108(9):
3128 - 3134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma
JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn.,
September 1, 2006;
8(4):
397 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek
Advances in the Therapy of Chronic Idiopathic Myelofibrosis
Oncologist,
September 1, 2006;
11(8):
929 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Blood,
September 1, 2006;
108(5):
1497 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Wagner-Ballon, H. Chagraoui, E. Prina, M. Tulliez, G. Milon, H. Raslova, J.-L. Villeval, W. Vainchenker, and S. Giraudier
Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin.
J. Immunol.,
June 1, 2006;
176(11):
6425 - 6433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
J. Clin. Oncol.,
November 20, 2005;
23(33):
8520 - 8530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Popat, A. Frost, E. Liu, R. May, V. Reddy, A. Durett, and J. Prchal
High Peripheral Blood CD34 Count in Patients with Idiopathic Myelofibrosis (IF) Is Not Due to Fibrosis and Altered Marrow Microenvironment.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
2439 - 2439.
[Abstract]
|
|
|
|
|
|
|
S. O'Brien, A. Tefferi, and P. Valent
Chronic Myelogenous Leukemia and Myeloproliferative Disease
Hematology,
January 1, 2004;
2004(1):
146 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bilhou-Nabera, C. Brigaudeau, D. Clay, J. Andrieux, J.-L. Lai, D. Brouty-Boye, C. Vignon, M.-J. Gharbi, M.-C. Le Bousse-Kerdiles, and V. Praloran
Does cytogenetic mosaicism in CD34+CD38low cells reflect the persistence of normal primitive hematopoietic progenitors in myeloid metaplasia with myelofibrosis?
Blood,
August 15, 2003;
102(4):
1551 - 1552.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
The Forgotten Myeloproliferative Disorder: Myeloid Metaplasia
Oncologist,
June 1, 2003;
8(3):
225 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak, G. Barosi, G. Tognoni, T. Barbui, G. Finazzi, R. Marchioli, and M. Marchetti
Chronic Myeloproliferative Disorders
Hematology,
January 1, 2003;
2003(1):
200 - 224.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
